Back to search

Peptide record

TPDB24048

Pep27anal1 Antibacterial Anticancer Toxicity standard
27 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB24048
Pep27anal1
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 27-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from Peptipedia, ACP740 _ACP240, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
MWKWFHNVLSSWQLLADKRPARDYNRK
Physicochemical Analysis
C159H237N47O38S1
CEGIT
RLKW
3446.98
10.87
7
2
12
+4
1.15
-1.081
61.48
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
17990
521.91
6
Residue Composition
number
2
A
3
R
2
N
2
D
0
C
0
E
1
Q
0
G
1
H
0
I
3
L
3
K
1
M
1
F
1
P
2
S
0
T
3
W
1
Y
1
V
Amino Acid Distribution
A: 2 R: 3 N: 2 D: 2 C: 0 E: 0 Q: 1 G: 0 H: 1 I: 0 L: 3 K: 3 M: 1 F: 1 P: 1 S: 2 T: 0 W: 3 Y: 1 V: 1
Chemical Descriptors
27
C159H237N47O38S1
3446.98
10.87
+4
1.15
-1.081
Free
L
Linear
Free
Anticancer
S. pneumoniae
Evidence Records 7 records
Evidence 1 Activity

Activity

IC50
IC50= 50 µM
Anticancer
50 µM

Target

Leukemia Cancer
AML-2
Blood

Assay & Model

MTT/MTS assay
18.67-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50= 53 µM
Anticancer
53 µM

Target

Leukemia Cancer
HL-60
Blood

Assay & Model

MTT/MTS assay
18.67-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 3 Activity

Activity

IC50
IC50= 47 µM
Anticancer
47 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT/MTS assay
18.67-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 4 Activity

Activity

IC50
IC50= 37 µM
Anticancer
37 µM

Target

Gastric Cancer
SNU-601
Stomach

Assay & Model

MTT/MTS assay
18.67-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 5 Activity

Activity

IC50
IC50= 55 µM
Anticancer
55 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
18.67-Min

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 6 Activity

Activity

0% Hemolysis
Toxicity
12.5 µM
Hemolytic Cytotoxic
0% Hemolysis | 12.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Functional and structural characteristics of anticancer peptide Pep27 analogues. | Cancer Cell Int | 2005
Evidence 7 Activity

Activity

% Hemolysis
Toxicity
0 %
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs(0% hemolysis at 0.19 µM, 0.39 µM, 0.78 µM, 1.56 µM, 3.12 µM, 6.25 µM, 12.5 µM) | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
Cancer Cell Int. 2005 Jul 11 5:21.